Publication

Relationship between Toxoplasma gondii Seropositivity and Acoustic Startle Response in an Inner-City Population

Downloadable Content

Persistent URL
Last modified
  • 03/14/2025
Type of Material
Authors
    Nick M. Massa, Emory UniversityErica Duncan, Emory UniversityTanja Jovanovic, Emory UniversityKimberly Kerley, Emory UniversityLei Weng, Emory UniversityLauren Gensler, Emory UniversitySamuel S. Lee, Emory UniversitySeth Davin Norrholm, Emory UniversityAbigail Powers, Emory UniversityLynn Almli, Emory UniversityCharles Gillespie, Emory UniversityKerry Ressler, Emory UniversityBrad Pearce, Emory University
Language
  • English
Date
  • 2017-03-01
Publisher
  • Elsevier: 12 months
Publication Version
Copyright Statement
  • © 2016 Elsevier Inc.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0889-1591
Volume
  • 61
Start Page
  • 176
End Page
  • 183
Grant/Funding Information
  • Supported by the National Institutes of Mental Health (MH071537 and MH096764 to K.J.R., and R01-MH092512 to B.D.P) and the Department of Veterans Affairs Merit Review Program (CX000974-01 to E.D.).
  • Infrastructure support from Grady Hospital; the Research and Development, Rehabilitation Research and Development, and Mental Health Service Lines, Atlanta Veterans Affairs Medical Center.
Supplemental Material (URL)
Abstract
  • Toxoplasma gondii (TOXO) is a neuroinvasive protozoan parasite that induces the formation of persistent cysts in mammalian brains. It infects approximately 1.1 million people in the United States annually. Latent TOXO infection is implicated in the etiology of psychiatric disorders, especially schizophrenia (SCZ), and has been correlated with modestly impaired cognition. The acoustic startle response (ASR) is a reflex seen in all mammals. It is mediated by a simple subcortical circuit, and provides an indicator of neural function. We previously reported the association of TOXO with slowed acoustic startle latency, an index of neural processing speed, in a sample of schizophrenia and healthy control subjects. The alterations in neurobiology with TOXO latent infection may not be specific to schizophrenia. Therefore we examined TOXO in relation to acoustic startle in an urban, predominately African American, population with mixed psychiatric diagnoses, and healthy controls. Physiological and diagnostic data along with blood samples were collected from 364 outpatients treated at an inner-city hospital. TOXO status was determined with an ELISA assay for TOXO-specific IgG. A discrete titer was calculated based on standard cut-points as an indicator of seropositivity, and the TOXO-specific IgG concentration served as serointensity. A series of linear regression models were used to assess the association of TOXO seropositivity and serointensity with ASR magnitude and latency in models adjusting for demographics and psychiatric diagnoses (PTSD, major depression, schizophrenia, psychosis, substance abuse). ASR magnitude was 11.5% higher in TOXO seropositive subjects compared to seronegative individuals (p = 0.01). This effect was more pronounced in models with TOXO serointensity that adjusted for sociodemographic covariates (F = 7.41, p = 0.0068; F = 10.05, p = 0.0017), and remained significant when psychiatric diagnoses were stepped into the models. TOXO showed no association with startle latency (t = 0.49, p = 0.63) in an unadjusted model, nor was TOXO associated with latency in models that included demographic factors. After stepping in individual psychiatric disorders, we found a significant association of latency with a diagnosis of PTSD (F = 5.15, p = 0.024), but no other psychiatric diagnoses, such that subjects with PTSD had longer startle latency. The mechanism by which TOXO infection is associated with high startle magnitude is not known, but possible mechanisms include TOXO cyst burden in the brain, parasite recrudescence, or molecular mimicry of a host epitope by TOXO. Future studies will focus on the neurobiology underlying the effects of latent TOXO infection as a potential inroad to the development of novel treatment targets for psychiatric disease.
Author Notes
  • Corresponding author: Brad D. Pearce, Ph.D., Rollins School of Public Health, Emory University, Office: 1518 Clifton Rd. CNR 4049 (1518-002-AA), Atlanta, GA 30322, Fax: 404-727-8737, Office Phone (404) 727-4914, bpearce@emory.edu
Keywords
Research Categories
  • Psychology, Behavioral
  • Health Sciences, Medicine and Surgery
  • Health Sciences, Public Health

Tools

Relations

In Collection:

Items